Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer. Academic Article uri icon



  • Amonafide (benzisoquinolinedione, nafidimide, NSC 308847) is an anticancer agent that functions as a DNA intercalator. Sixteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given amonafide at an initial dose of 300 mg/m2 i.v. daily for 5 days every 21 days. No major objective responses were observed among the 14 patients adequately treated (95% confidence limits 0-20%). Local reactions at the injection site or phlebitis were seen in 14 of the 16 patients. Leukopenia (44%), nausea or vomiting (38%), and thrombocytopenia and rash (each 25%) were also noted. With the low response rate and the toxicity observed, amonafide at this dosage and schedule has limited use in the treatment of non-small-cell lung cancer.

publication date

  • April 1, 1991



  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Imides
  • Intercalating Agents
  • Isoquinolines
  • Lung Neoplasms


Scopus Document Identifier

  • 0025805839

PubMed ID

  • 1851387

Additional Document Info


  • 14


  • 2